None

Pet Dogs Help Biotech Startups Find New Weapons to Fight Cancer

A few weeks back, a black-and-white terrier mix named Chance entered a clinical trial for a drug that may offer a completely new way to combat cancer—not only in dogs, but in people, too. The drug,...

Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of ...

Study Marks First Time Cancer Patients Are Treated With Oncolytic Vaccinia Virus in Germany

Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate

SAN DIEGO, CA -- (Marketwire) -- 05/30/12 -- Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-v...

Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic ...

Early Evidence of Efficient Virotherapeutic Replication and Cancer Cell Lysis in GL-ONC1 Treated Patients

First Patient Treated in Genelux Phase I Trial With GL-ONC1 at Memorial Sloan Kettering Cancer ...

Study to Include Cancer Patients With Malignant Mesothelioma and Malignant Pleural Effusions From Other Primary Tumors

Genelux Corporation Announces First Patient Dosed in Phase I Combination Clinical Trial of GL-ONC1

SAN DIEGO, CA -- (Marketwire) -- 06/14/12 -- Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus-based oncolytic (cancer-killing) therapies and companion diagno...

Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers

SAN DIEGO, CA -- (Marketwire) -- 05/31/12 -- Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-vi...

Genelux Corporation Announces Early Results of a Phase I/II Clinical Trial of Virotherapeutic GL-ONC1 in Advanced Peritoneal Cavity Cancers

SAN DIEGO, CA -- (Marketwire) -- 11/01/12 -- Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics, anno...

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

In 2001, Jackson et al. reported that murine IL-4 expression by a recombinant ectromelia virus caused enhanced morbidity and lethality in resistant C57BL/6 mice as well as overcame protective immune m...

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recentl...